180 related articles for article (PubMed ID: 23132512)
1. Cytogenetics and molecular cytogenetics in diffuse large B-cell lymphoma (DLBCL).
Nedomova R; Papajik T; Prochazka V; Indrak K; Jarosova M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Sep; 157(3):239-47. PubMed ID: 23132512
[TBL] [Abstract][Full Text] [Related]
2. The biology of human lymphoid malignancies revealed by gene expression profiling.
Staudt LM; Dave S
Adv Immunol; 2005; 87():163-208. PubMed ID: 16102574
[TBL] [Abstract][Full Text] [Related]
3. Molecular heterogeneity of diffuse large B-cell lymphoma: implications for disease management and prognosis.
Rossi D; Gaidano G
Hematology; 2002 Aug; 7(4):239-52. PubMed ID: 14972786
[TBL] [Abstract][Full Text] [Related]
4. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma.
Obermann EC; Csato M; Dirnhofer S; Tzankov A
J Clin Pathol; 2009 Oct; 62(10):903-7. PubMed ID: 19783718
[TBL] [Abstract][Full Text] [Related]
5. Chromosome abnormalities in diffuse large B-cell lymphomas: analysis of 231 Chinese patients.
Zhao X; Fan R; Lin G; Wang X
Hematol Oncol; 2013 Sep; 31(3):127-35. PubMed ID: 23135954
[TBL] [Abstract][Full Text] [Related]
6. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
[TBL] [Abstract][Full Text] [Related]
7. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1.
Hoeller S; Schneider A; Haralambieva E; Dirnhofer S; Tzankov A
Histopathology; 2010 Jul; 57(1):73-80. PubMed ID: 20579129
[TBL] [Abstract][Full Text] [Related]
8. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma.
Iqbal J; Greiner TC; Patel K; Dave BJ; Smith L; Ji J; Wright G; Sanger WG; Pickering DL; Jain S; Horsman DE; Shen Y; Fu K; Weisenburger DD; Hans CP; Campo E; Gascoyne RD; Rosenwald A; Jaffe ES; Delabie J; Rimsza L; Ott G; Müller-Hermelink HK; Connors JM; Vose JM; McKeithan T; Staudt LM; Chan WC;
Leukemia; 2007 Nov; 21(11):2332-43. PubMed ID: 17625604
[TBL] [Abstract][Full Text] [Related]
9. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma.
Iqbal J; Neppalli VT; Wright G; Dave BJ; Horsman DE; Rosenwald A; Lynch J; Hans CP; Weisenburger DD; Greiner TC; Gascoyne RD; Campo E; Ott G; Müller-Hermelink HK; Delabie J; Jaffe ES; Grogan TM; Connors JM; Vose JM; Armitage JO; Staudt LM; Chan WC
J Clin Oncol; 2006 Feb; 24(6):961-8. PubMed ID: 16418494
[TBL] [Abstract][Full Text] [Related]
10. BCL2 mutations in diffuse large B-cell lymphoma.
Schuetz JM; Johnson NA; Morin RD; Scott DW; Tan K; Ben-Nierah S; Boyle M; Slack GW; Marra MA; Connors JM; Brooks-Wilson AR; Gascoyne RD
Leukemia; 2012 Jun; 26(6):1383-90. PubMed ID: 22189900
[TBL] [Abstract][Full Text] [Related]
11. Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma: chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival.
Yoshioka T; Miura I; Kume M; Takahashi N; Okamoto M; Ichinohasama R; Yoshino T; Yamaguchi M; Hirokawa M; Sawada K; Nakamura S
Genes Chromosomes Cancer; 2005 Feb; 42(2):149-57. PubMed ID: 15543600
[TBL] [Abstract][Full Text] [Related]
12. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
Lenz G; Wright GW; Emre NC; Kohlhammer H; Dave SS; Davis RE; Carty S; Lam LT; Shaffer AL; Xiao W; Powell J; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Campo E; Jaffe ES; Delabie J; Smeland EB; Rimsza LM; Fisher RI; Weisenburger DD; Chan WC; Staudt LM
Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13520-5. PubMed ID: 18765795
[TBL] [Abstract][Full Text] [Related]
13. Expression of LMO2 is associated with t(14;18)/IGH-BCL2 fusion but not BCL6 translocations in diffuse large B-cell lymphoma.
Durnick DK; Law ME; Maurer MJ; Natkunam Y; Levy R; Lossos IS; Kurtin PJ; McPhail ED
Am J Clin Pathol; 2010 Aug; 134(2):278-81. PubMed ID: 20660332
[TBL] [Abstract][Full Text] [Related]
14. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of immunohistochemistry in identification of prognostically important subgroups (GCB and ABC) in a heterogeneous group of diffuse large B-cell lymphomas--a review article.
Jabłońska J; Jesionek-Kupnicka D
Pol J Pathol; 2008; 59(3):121-7. PubMed ID: 19097355
[TBL] [Abstract][Full Text] [Related]
16. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement.
Le Gouill S; Talmant P; Touzeau C; Moreau A; Garand R; Juge-Morineau N; Gaillard F; Gastinne T; Milpied N; Moreau P; Harousseau JL; Avet-Loiseau H
Haematologica; 2007 Oct; 92(10):1335-42. PubMed ID: 18024371
[TBL] [Abstract][Full Text] [Related]
17. Characterization of genomic imbalances in diffuse large B-cell lymphoma by detailed SNP-chip analysis.
Scholtysik R; Kreuz M; Hummel M; Rosolowski M; Szczepanowski M; Klapper W; Loeffler M; Trümper L; Siebert R; Küppers R;
Int J Cancer; 2015 Mar; 136(5):1033-42. PubMed ID: 25042405
[TBL] [Abstract][Full Text] [Related]
18. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas.
Kluiver J; Poppema S; de Jong D; Blokzijl T; Harms G; Jacobs S; Kroesen BJ; van den Berg A
J Pathol; 2005 Oct; 207(2):243-9. PubMed ID: 16041695
[TBL] [Abstract][Full Text] [Related]
19. The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma.
Ruminy P; Etancelin P; Couronné L; Parmentier F; Rainville V; Mareschal S; Bohers E; Burgot C; Cornic M; Bertrand P; Lenormand B; Picquenot JM; Jardin F; Tilly H; Bastard C
Leukemia; 2011 Apr; 25(4):681-8. PubMed ID: 21233831
[TBL] [Abstract][Full Text] [Related]
20. ID3 mutations are recurrent events in double-hit B-cell lymphomas.
Gebauer N; Bernard V; Feller AC; Merz H
Anticancer Res; 2013 Nov; 33(11):4771-8. PubMed ID: 24222112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
